174 related articles for article (PubMed ID: 26732684)
1. Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing.
das Neves J; Martins JP; Sarmento B
Adv Drug Deliv Rev; 2016 Aug; 103():20-32. PubMed ID: 26732684
[TBL] [Abstract][Full Text] [Related]
2. Development of dapivirine vaginal ring for HIV prevention.
Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
[TBL] [Abstract][Full Text] [Related]
4. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicine in the development of anti-HIV microbicides.
das Neves J; Nunes R; Rodrigues F; Sarmento B
Adv Drug Deliv Rev; 2016 Aug; 103():57-75. PubMed ID: 26829288
[TBL] [Abstract][Full Text] [Related]
6. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
McBride JW; Malcolm RK; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Devlin B; Boyd P
Int J Pharm; 2019 Jun; 564():207-213. PubMed ID: 30999049
[TBL] [Abstract][Full Text] [Related]
7. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
8. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action.
Fetherston SM; Boyd P; McCoy CF; McBride MC; Edwards KL; Ampofo S; Malcolm RK
Eur J Pharm Sci; 2013 Feb; 48(3):406-15. PubMed ID: 23266465
[TBL] [Abstract][Full Text] [Related]
9. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
Holt JD; Cameron D; Dias N; Holding J; Muntendam A; Oostebring F; Dreier P; Rohan L; Nuttall J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3761-70. PubMed ID: 25845860
[TBL] [Abstract][Full Text] [Related]
10. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
Friend DR; Kiser PF
Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
[TBL] [Abstract][Full Text] [Related]
12. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
[TBL] [Abstract][Full Text] [Related]
13. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.
Bunge KE; Dezzutti CS; Rohan LC; Hendrix CW; Marzinke MA; Richardson-Harman N; Moncla BJ; Devlin B; Meyn LA; Spiegel HM; Hillier SL
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):498-505. PubMed ID: 26565716
[TBL] [Abstract][Full Text] [Related]
15. Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring.
McCoy CF; Murphy DJ; Boyd P; Derrick T; Spence P; Devlin B; Malcolm RK
J Pharm Sci; 2017 Aug; 106(8):2015-2025. PubMed ID: 28456732
[TBL] [Abstract][Full Text] [Related]
16. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
[TBL] [Abstract][Full Text] [Related]
17. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence.
Spence P; Nel A; van Niekerk N; Derrick T; Wilder S; Devlin B
J Pharm Biomed Anal; 2016 Jun; 125():94-100. PubMed ID: 27016673
[TBL] [Abstract][Full Text] [Related]
18. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
Dezzutti CS; Yandura S; Wang L; Moncla B; Teeple EA; Devlin B; Nuttall J; Brown ER; Rohan LC
Pharm Res; 2015 Nov; 32(11):3768-81. PubMed ID: 26078001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
